Greenberg Traurig Represents Entera Bio in $10M Private Placement

The global law firm advised the Israel-based biotech company on the financing led by BVF Partners.

Apr. 6, 2026 at 6:55pm

Got story updates? Submit your updates here. ›

A minimalist studio still life featuring a group of polished, geometric objects in shades of gray, conceptually representing the abstract ideas of corporate finance, investment, and biotechnology research and development.A private placement financing led by a prominent healthcare investor will support a biotech company's efforts to develop more convenient oral versions of peptide and protein therapies.Today in Miami

Greenberg Traurig, P.A., a global law firm, advised Israel-based Entera Bio Ltd. (Nasdaq: ENTX), a clinical-stage biotechnology company, on a $10 million private placement financing led by BVF Partners.

Why it matters

This financing will help support Entera Bio's continued development of its oral peptide and protein replacement therapies, which could provide more convenient treatment options for patients compared to injectable formulations.

The details

Entera Bio is a clinical-stage biotech company focused on developing oral versions of peptide and protein-based therapeutics. The $10 million private placement was led by BVF Partners, a prominent healthcare-focused investment firm.

  • The financing was completed on April 6, 2026.

The players

Greenberg Traurig, P.A.

A global law firm that advised Entera Bio on the private placement financing.

Entera Bio Ltd.

An Israel-based, clinical-stage biotechnology company focused on developing oral peptide and protein replacement therapies.

BVF Partners

A prominent healthcare-focused investment firm that led the $10 million private placement in Entera Bio.

Got photos? Submit your photos here. ›

The takeaway

This financing demonstrates continued investor interest in innovative biotechnology companies developing novel therapeutic approaches, even in challenging market conditions.